Join Baptist Health Miami Cardiac & Vascular Institute experts Jonathan Fialkow, M.D., FACC, Adedapo (Dapo) Iluyomade, M.D., and Sergiu Darabant, M.D. as they discuss how this development could revolutionize the approach to combating cardiometabolic diseases through targeting inflammation, and what it means for your patients. In this enlightening episode, we delve into the groundbreaking FDA approval of colchicine for the prevention of major adverse cardiovascular events. Join us as we explore the journey of this ancient remedy, traditionally used for gout, now emerging as a promising agent in cardioprotection. We dissect the pivotal clinical trials and evidence-based data that led to this landmark decision, shedding light on colchicine's mechanism of action and its potential role in reshaping preventive cardiology.  Guests: Jonathan Fialkow, M.D., FACC                          Chief Medical Executive for Population Health, Value and Primary Care Deputy Director of Miami Cardiac & Vascular InstituteChief of Cardiology, Baptist Hospital Adedapo (Dapo) Iluyomade, M.D., Preventive Cardiologist, Baptist Health Miami Cardiac & Vascular Institute Sergiu Darabant, M.D., Cardiologist, Baptist Health Miami Cardiac & Vascular Institute 

Ver todos los episodios